Metoclopramide Accord

Metoclopramide, the active ingredient in Metoclopramide Accord, is a dopamine antagonist presented as an oral dosage form for oral use. It is employed to manage nausea, vomiting, gastroparesis, and related gastrointestinal disorders in adult patients. GNH USA supplies Metoclopramide Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metoclopramide acts on the dopaminergic pathways and gastrointestinal motility to alleviate several conditions. - Nausea and vomiting: reduces episodes by blocking dopamine receptors in the chemoreceptor trigger zone. - Gastroparesis: enhances gastric emptying and improves gastric motility. - Gastro‑oesophageal reflux disease (GERD): decreases reflux symptoms by promoting gastric clearance. - Pre‑ and post‑operative nausea: prevents nausea associated with surgical procedures and anesthesia.

Metoclopramide may cause a range of adverse reactions.

Common Side Effects: - Drowsiness: mild sedation or sleepiness. - Restlessness: feelings of inner tension or agitation. - Diarrhea: increased bowel movements. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Extrapyramidal symptoms: involuntary muscle movements or tremor. - Tardive dyskinesia: persistent, potentially irreversible facial or limb movements. - Neuroleptic malignant syndrome: rare, life‑threatening reaction with fever and muscle rigidity.

Metoclopramide requires careful use in certain populations and clinical situations. - Renal function assessment: adjust use in patients with impaired kidney function. - Monitor for extrapyramidal symptoms: watch for involuntary movements, especially with prolonged therapy. - Avoid in seizure disorders: may lower seizure threshold. - Use caution in the elderly: increased sensitivity to central nervous system effects. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Metoclopramide can interact with several drug classes, influencing safety and efficacy.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of severe hypertension. - Central nervous system depressants: additive sedation. - Anticholinergic agents: may reduce prokinetic effect.

Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors (SSRIs): potential for serotonin syndrome. - Antipsychotics: may diminish antiemetic benefit. - Digoxin: possible increase in serum levels.